he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查阅信源地址
上一页:哪些抗菌用药可诱发癫痫?
- 2022-05-052020世界肾脏日:中国在秘密行动
- 2022-05-03生酮蔬果对不同病因和发作形式癫痫的如何?
- 2022-04-25必要性癫痫的先兆研究
- 2022-04-212013年国际抗癫痫协会抗癫痫药使用指南
- 2021-11-29全省癫痫病治疗专科
- 2021-10-19全国高校癫痫病治疗专科
- 外科手术治疗癫痫病费用大约是多少钱
- 学龄前癫痫病的治疗费用
- 儿童癫痫病的治疗支出
- 治疗者儿童癫痫病大概需要多少费用
- 癫痫病治疗费用是从多少钱
- 吡仑帕奈辅助用药可改善部分发作型癫痫患者的患者
- 2013年国际抗癫痫协会抗癫痫药使用指南
- 哪些抗菌用药可诱发癫痫?
- 诺华银屑病药物 Secukinumab 比依那西普好
- 癫痫病治疗费用是从多少钱
- 长期用药治疗慢性疼痛或弊大于益
- 如何诊断妇科炎症?做什么检查?
- Nat Commun:SIRT6恢复能量稳态延缓衰老
- 第二届微创、超声介入学科发展及临床应用研讨会
- 【预约直播】铿锵的论道 不炎,越来越多--「郁金香论坛」学术沙龙即将举行
- 什么是肿痛?如何缓解肿痛?
- 研究发现,置入支架接近手术打开动脉的再堵塞风险
- 介绍几种治疗牛皮癣的菜肴
- 继发性痛经和原发性痛经有什么区别?
- 糖尿病能吃玉米吗?
- JAHA:β阻塞性睡眠呼吸暂停综合征患者夜间心律失常和心率波动
- 男人吃牡蛎有什么好处?
- Blood:巨噬细胞Epo受体信号促进应激造血时红系的分化
- 羊角风有什么症状?
- 北京大学人民医院第五届男性健康沙龙
- 著名女演员愤怒地告诉莆田妇科医院 要求在全国媒体上公开道歉
- Nucala(mepolizumab)首个能显著减少高嗜酸性粒细胞综合征患者耀斑的治疗方法
- 叉烧包的馅怎么做 很好吃
- 十个女人,八个贫血,五种常见的便宜货,让你充满气血
- 精囊炎的症状是什么?
- Neuroscience:对侧噪声对语音清晰度的影响
- BJOG:口服补充剂对孕期微生物群的影响
- 验孕┃早孕试纸不准吗?为什么要做早孕检查?
- 如何预防炎症 滥用抗生素小心得这种病
- 胃胀气的症状 这里疼痛小心是胃胀气
- 女人怕男人看到手机里有它
- 月经周期计算 女性如何计算自己的周期?
- 认真癫痫病需要多少钱
- 20131029养生堂:王文志讲心脑血管传染病的预防
- 癫痫病吃饱什么好
- 治疗癫痫病先以北京哪家医院好
- 怎么用生物科学的方法治疗癫痫病
- 癫痫病的早期症状 患有癫痫万不能不吃它(2)
- 成年人癫痫病病因有哪些
- 长期酗酒 只需警惕 Marchiafa-Bignami 病
- 治疗小儿癫痫病要多银两
- 乙肝疫苗多久打一次 有哪些须知
- 三庚酸酯或可治疗1型转运体瑕疵综合征
- 癫痫病的最佳化疗期
- 老年人得了癫痫病有什么副作用